E. D. Thomas, C. D. Buckner, M. Banaji, R. A. Clift, A. Fefer et al., One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation, Blood. avr, vol.49, issue.4, pp.511-544, 1977.

M. M. Horowitz, R. P. Gale, P. M. Sondel, J. M. Goldman, J. Kersey et al., Graft--versus--leukemia reactions after bone marrow transplantation, Blood. 1 févr, vol.75, issue.3, pp.555-62, 1990.

E. A. Copelan, Hematopoietic stem--cell transplantation, N Engl J Med. 27 avr, vol.354, issue.17, pp.1813-1839, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00849640

L. O. Jacobson, E. L. Simmons, E. K. Marks, and J. H. Eldredge, Recovery from radiation injury. Science. 4 mai, vol.113, pp.510-511, 1951.

J. E. Till and E. A. Mcculloch, A direct measurement of the radiation sensitivity of normal mouse bone marrow cells, Radiat Res. août, vol.178, issue.2, pp.3-7, 1961.

A. J. Becker, E. A. Mcculloch, and J. E. Till, Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells, Nature. 2 févr, vol.197, pp.452-456, 1963.

L. Siminovitch, E. A. Mcculloch, and J. E. Till, THE DISTRIBUTION OF COLONY--FORMING CELLS AMONG SPLEEN COLONIES, J Cell Comp Physiol. déc, vol.62, pp.327-363, 1963.

L. Siminovitch, J. E. Till, and E. A. Mcculloch, DECLINE IN COLONY--FORMING ABILITY OF MARROW CELLS SUBJECTED TO SERIAL TRANSPLANTATION INTO IRRADIATED MICE, J Cell Comp Physiol. août, vol.64, pp.23-31, 1964.

T. Lapidot, C. Sirard, J. Vormoor, B. Murdoch, T. Hoang et al., A cell initiating human acute myeloid leukaemia after transplantation into SCID mice, Nature. 17 févr, vol.367, issue.6464, pp.645-653, 1994.

J. Sarry, K. Murphy, R. Perry, P. V. Sanchez, A. Secreto et al., Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2R?c--deficient mice, J Clin Invest, vol.121, issue.1, pp.384-95, 2011.

J. Dausset and H. Brecy, Identical nature of the leucocyte antigens detectable in monozygotic twins by means of immune iso--leuco--agglutinins, Nature. 21 déc, vol.180, issue.4599, p.1430, 1957.

J. Dausset, The major histocompatibility complex in man, Science. 25 sept, vol.213, issue.4515, pp.1469-74, 1981.

A. Chevailler, S. Fournel, B. Gubler, J. Lelièvre, E. Seillès et al., Immunologie fondamentale et immunopathologie: enseignements thématique et intégré : tissu lymphoïde et sanguin, immunopathologie et immuno--intervention, 2018.

P. L. Weiden, K. M. Sullivan, N. Flournoy, R. Storb, and E. D. Thomas, Antileukemic effect of chronic graft--versus--host disease: contribution to improved survival after allogeneic marrow transplantation, N Engl J Med, vol.18, issue.25, pp.1529-1562, 1981.

D. Bonnet, E. H. Warren, P. D. Greenberg, J. E. Dick, and S. R. Riddell, CD8(+) minor histocompatibility antigen--specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells, Proc Natl Acad Sci, vol.96, issue.15, pp.8639-8683, 1999.

M. Vogt, J. W. Van-den-muijsenberg, E. Goulmy, E. Spierings, P. Kluck et al., The DBY gene codes for an HLA--DQ5--restricted human male--specific minor histocompatibility antigen involved in graft--versus--host disease, Blood. 15 avr, vol.99, issue.8, pp.3027-3059, 2002.

M. Bleakley and S. R. Riddell, Molecules and mechanisms of the graft--versus--leukaemia effect, Nat Rev Cancer. mai, vol.4, issue.5, pp.371-80, 2004.

P. Loiseau, M. Busson, M. Balere, A. Dormoy, J. Bignon et al., HLA Association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA--A, --B, --C, --DRB1, or --DQB1 is strongly associated with overall survival, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. août, vol.13, issue.8, pp.965-74, 2007.

E. Goulmy, R. Schipper, J. Pool, E. Blokland, J. H. Falkenburg et al., Mismatches of minor histocompatibility antigens between HLA--identical donors and recipients and the development of graft--versus--host disease after bone marrow transplantation, N Engl J Med. 1 févr, vol.334, issue.5, pp.281-286, 1996.

J. Falkenburg, L. Van-de-corput, E. Marijt, and R. Willemze, Minor histocompatibility antigens in human stem cell transplantation, Exp Hematol. sept, vol.31, issue.9, pp.743-51, 2003.

Y. Reisner and M. F. Martelli, Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells, Immunol Today. sept, vol.16, issue.9, pp.437-477, 1995.

Y. Reisner, D. Hagin, and M. F. Martelli, Haploidentical hematopoietic transplantation: current status and future perspectives, Blood. 1 déc, vol.118, issue.23, pp.6006-6023, 2011.

A. Bacigalupo, K. Ballen, D. Rizzo, S. Giralt, H. Lazarus et al., Defining the intensity of conditioning regimens: working definitions, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. déc, vol.15, issue.12, pp.1628-1661, 2009.

H. J. Deeg and B. M. Sandmaier, Who is fit for allogeneic transplantation? Blood. 2 déc, vol.116, pp.4762-70, 2010.

J. Finke, W. A. Bethge, C. Schmoor, H. D. Ottinger, M. Stelljes et al., Standard graft--versus--host disease prophylaxis with or without anti--T--cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open--label, multicentre phase 3 trial, Lancet Oncol. sept, vol.10, issue.9, pp.855-64, 2009.

N. Kröger, C. Solano, C. Wolschke, G. Bandini, F. Patriarca et al., Antilymphocyte Globulin for Prevention of Chronic Graft--versus--Host Disease, N Engl J Med. 7 janv, vol.374, issue.1, pp.43-53, 2016.

B. Speck, A. Gratwohl, C. Nissen, B. Osterwalder, M. Müller et al.,

, Schweiz Med Wochenschr. 12 déc, vol.111, issue.50, pp.1975-1982, 1981.

H. J. Deeg, R. Storb, E. D. Thomas, N. Flournoy, M. S. Kennedy et al., Cyclosporine as prophylaxis for graft--versus--host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia, Blood. juin, vol.65, issue.6, pp.1325-1359, 1985.

S. Belaiche, N. Yafour, S. Balcaen, Y. Beguin, C. Borel et al.,

, Pathol Biol (Paris). août, vol.62, issue.4, pp.197-203, 2014.

R. Storb, H. J. Deeg, J. Whitehead, F. Appelbaum, P. Beatty et al., Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia, N Engl J Med. 20 mars, vol.314, issue.12, pp.729-764, 1986.

M. Kharfan--dabaja, R. Mhaskar, T. Reljic, J. Pidala, J. B. Perkins et al., Mycophenolate mofetil versus methotrexate for prevention of graft--versus--host disease in people receiving allogeneic hematopoietic stem cell transplantation. Cochrane Haematological Malignancies Group, éditeur. Cochrane Database Syst Rev

D. Sur,

R. Ram, M. Yeshurun, L. Vidal, O. Shpilberg, -. Gafter et al., Mycophenolate mofetil vs. methotrexate for the prevention of graft--versus--host--disease----systematic review and meta--analysis, Leuk Res. mars, vol.38, issue.3, pp.352-60, 2014.

M. Körbling and P. Anderlini, Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood, vol.98, pp.2900-2908, 2001.

M. A. Pulsipher, P. Chitphakdithai, B. R. Logan, B. E. Shaw, J. R. Wingard et al., Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program, Blood. 3 janv, vol.121, issue.1, pp.197-206, 2013.

K. K. Ballen, R. J. King, P. Chitphakdithai, C. D. Bolan, E. Agura et al., The national marrow donor program 20 years of unrelated donor hematopoietic cell transplantation, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. sept, vol.14, issue.9, pp.2-7, 2008.

I. Yakoub--agha, F. Mesnil, M. Kuentz, J. M. Boiron, N. Ifrah et al., Allogeneic marrow stem--cell transplantation from human leukocyte antigen--identical siblings versus human leukocyte antigen--allelic--matched unrelated donors (10/10) in patients with standard--risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy, J Clin Oncol Off J Am Soc Clin Oncol. 20 déc, vol.24, issue.36, pp.5695-702, 2006.

V. Gupta, M. S. Tallman, W. He, B. R. Logan, E. Copelan et al., Comparable survival after HLA--well--matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood. 16 sept, vol.116, pp.1839-1887, 2010.

H. E. Broxmeyer, G. W. Douglas, G. Hangoc, S. Cooper, J. Bard et al., Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells, Proc Natl Acad Sci, vol.86, issue.10, pp.3828-3860, 1989.

E. Gluckman, H. A. Broxmeyer, A. D. Auerbach, H. S. Friedman, G. W. Douglas et al., Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical--cord blood from an HLA--identical sibling, N Engl J Med, vol.321, issue.17, pp.1174-1182, 1989.

F. Aversa, A. Tabilio, A. Velardi, I. Cunningham, A. Terenzi et al., Treatment of high--risk acute leukemia with T--cell--depleted stem cells from related donors with one fully mismatched HLA haplotype, N Engl J Med, vol.339, issue.17, pp.1186-93, 1998.

L. Luznik, S. Jalla, L. W. Engstrom, R. Iannone, and E. J. Fuchs, Durable engraftment of major histocompatibility complex--incompatible cells after nonmyeloablative conditioning with fludarabine, low--dose total body irradiation, and posttransplantation cyclophosphamide, Blood. 1 déc, vol.98, issue.12, pp.3456-64, 2001.

L. Luznik, P. V. O'donnell, H. J. Symons, A. R. Chen, M. S. Leffell et al., HLA--haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high--dose, posttransplantation cyclophosphamide, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. juin, vol.14, issue.6, pp.641-50, 2008.

C. G. Kanakry, S. Ganguly, M. Zahurak, -. Bolaños, J. Thoburn et al., Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide, Sci Transl Med, vol.5, issue.211, pp.211-157, 2013.

R. J. Jones, J. P. Barber, M. S. Vala, M. I. Collector, S. H. Kaufmann et al., Assessment of aldehyde dehydrogenase in viable cells, Blood. 15 mai, vol.85, issue.10, pp.2742-2748, 1995.

D. Blaise, S. Fürst, R. Crocchiolo, J. El--cheikh, A. Granata et al., Haploidentical T Cell--Replete Transplantation with Post--Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen--Matched Related or Unrelated Donor, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. janv, vol.22, issue.1, pp.119-143, 2016.

Z. A. Bashey, X. Zhang, S. Brown, K. Jackson, L. E. Morris et al., Comparison of outcomes following transplantation with T--replete HLA--haploidentical donors using post--transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older, Bone Marrow Transplant. juin, vol.53, issue.6, pp.756-63, 2018.

A. Bashey, X. Zhang, C. A. Sizemore, K. Manion, S. Brown et al., T--cell--replete HLA--haploidentical hematopoietic transplantation for hematologic malignancies using post--transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA--matched related and unrelated donor transplantation, J Clin Oncol Off J Am Soc Clin Oncol. 1 avr, vol.31, issue.10, pp.1310-1316, 2013.

N. Ghosh, R. Karmali, V. Rocha, K. W. Ahn, A. Digilio et al., Reduced--Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA--Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis, J Clin Oncol Off J Am Soc Clin Oncol. 10 sept, vol.34, issue.26, pp.3141-3150, 2016.

C. Martínez, J. Gayoso, C. Canals, H. Finel, K. Peggs et al., Post--Transplantation Cyclophosphamide--Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation, J Clin Oncol, vol.35, issue.30, pp.3425-3457, 2017.

S. R. Mccurdy, Y. L. Kasamon, C. G. Kanakry, -. Bolaños, J. Tsai et al., Comparable composite endpoints after HLA--matched and HLA--haploidentical transplantation with post--transplantation cyclophosphamide, Haematologica. févr, vol.102, issue.2, pp.391-400, 2017.

R. Duléry, A. Ménard, S. Chantepie, J. El--cheikh, S. François et al., Sequential Conditioning with Thiotepa in T Cell--Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo--Mismatched, and Unrelated Donors, Biol Blood Marrow Transplant. mai, vol.24, issue.5, pp.1013-1034, 2018.

R. Devillier, F. Legrand, J. Rey, L. Castagna, S. Fürst et al., HLA--Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single--Center Donor Comparison, Biol Blood Marrow Transplant. juill, vol.24, issue.7, pp.1449-54, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02143551

N. Gorin, M. Labopin, D. Blaise, M. Groot, G. Socié et al., Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Cancer, 2019.

S. O. Ciurea, M. Zhang, A. A. Bacigalupo, A. Bashey, F. R. Appelbaum et al., Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia, Blood. 20 août, vol.126, issue.8, pp.1033-1073, 2015.

C. G. Brunstein, E. J. Fuchs, S. L. Carter, C. Karanes, L. J. Costa et al., Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA--mismatched related bone marrow or unrelated double umbilical cord blood grafts, Blood. 14 juill, vol.118, issue.2, pp.282-290, 2011.

A. Ruggeri, M. Labopin, G. Sanz, S. Piemontese, W. Arcese et al., Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia, Leukemia. sept, vol.29, issue.9, pp.1891-900, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02007180

F. Giannotti, M. Labopin, R. Shouval, J. Sanz, W. Arcese et al., Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT--Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine, J Hematol OncolJ Hematol Oncol. déc, vol.11, issue.1, p.110, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02143659

N. Kekre and J. H. Antin, Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist, Blood. 17 juill, vol.124, issue.3, pp.334-377, 2014.

T. A. Gooley, J. W. Chien, S. A. Pergam, S. Hingorani, M. L. Sorror et al., Reduced mortality after allogeneic hematopoietic--cell transplantation, N Engl J Med, vol.363, issue.22, pp.2091-101, 2010.

R. E. Billingham, The biology of graft--versus--host reactions, Harvey Lect, vol.62, pp.21-78, 19671966.

G. Socié and B. R. Blazar, Acute graft--versus--host disease: from the bench to the bedside, Blood, vol.12, issue.20, pp.4327-4363, 2009.

H. Glucksberg, R. Storb, A. Fefer, C. D. Buckner, P. E. Neiman et al., Clinical manifestations of graft--versus--host disease in human recipients of marrow from HL--A--matched sibling donors, Transplantation. oct, vol.18, issue.4, pp.295-304, 1974.

P. J. Martin, G. Schoch, L. Fisher, V. Byers, C. Anasetti et al., A retrospective analysis of therapy for acute graft--versus--host disease: initial treatment, Blood, vol.76, issue.8, pp.1464-72, 1990.

K. M. Sullivan, E. Agura, C. Anasetti, F. Appelbaum, C. Badger et al., Chronic graft--versus--host disease and other late complications of bone marrow transplantation, Semin Hematol. juill, vol.28, issue.3, pp.250-259, 1991.

A. C. Harris, R. Young, S. Devine, W. J. Hogan, F. Ayuk et al., Multicenter Standardization of Acute Graft--versus--Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. janv, vol.22, issue.1, pp.4-10, 2016.

H. M. Schoemans, S. J. Lee, J. L. Ferrara, D. Wolff, J. E. Levine et al., EBMT--NIH--CIBMTR Task Force position statement on standardized terminology & guidance for graft--versus--host disease assessment, Bone Marrow Transplant, vol.53, issue.11, pp.1401-1416, 2018.

J. Ferrara, J. E. Levine, P. Reddy, and E. Holler, Graft--versus--host disease, Lancet Lond Engl. 2 mai, vol.373, issue.9674, pp.1550-61, 2009.

O. Penack, M. Marchetti, T. Ruutu, M. Aljurf, A. Bacigalupo et al., Prophylaxis and management of graft versus host disease after stem--cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation, Lancet Haematol. févr, vol.7, issue.2, pp.157-67, 2020.

G. Socié and J. Ritz, Current issues in chronic graft--versus--host disease, Blood. 17 juill, vol.124, issue.3, pp.374-84, 2014.

M. H. Jagasia, H. T. Greinix, M. Arora, K. M. Williams, D. Wolff et al., National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft--versus--Host Disease: I. The 2014 Diagnosis and Staging Working Group report, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. mars, vol.21, issue.3, pp.389-401, 2015.

M. Tomblyn, T. Chiller, H. Einsele, R. Gress, K. Sepkowitz et al., Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.15, issue.10, pp.1143-238, 2009.

C. C. Blyth, N. M. Gilroy, S. D. Guy, S. T. Chambers, E. Y. Cheong et al., Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, Intern Med J. déc, vol.44, issue.12b, pp.1333-1382, 2014.

J. Styczynski, W. Van-der-velden, C. P. Fox, D. Engelhard, R. De-la-camara et al., Management of Epstein--Barr Virus infections and post--transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation, Sixth European Conference on Infections in Leukemia, vol.101, pp.803-814, 2016.

E. Brissot, T. Alsuliman, B. Gruson, E. Hermet, Y. Tirefort et al., How to manage EBV reactivation and EBV--PTLD, CMV and human herpesvirus 6 reactivation and infection after allogeneic stem cell transplantation: A

, Bull Cancer (Paris). déc, vol.104, issue.12S, pp.181-188, 2017.

G. B. Mcdonald, P. Sharma, D. E. Matthews, H. M. Shulman, and E. D. Thomas, Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors, Hepatol Baltim Md. févr, vol.4, issue.1, pp.116-138, 1984.

R. J. Jones, K. S. Lee, W. E. Beschorner, V. G. Vogel, L. B. Grochow et al., Venoocclusive disease of the liver following bone marrow transplantation, Transplantation. déc, vol.44, issue.6, pp.778-83, 1987.

M. Mohty, F. Malard, M. Abecassis, E. Aerts, A. S. Alaskar et al., Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno--occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation, Bone Marrow Transplant. juill, vol.51, issue.7, pp.906-918, 2016.

C. Q. Fan and J. M. Crawford, Sinusoidal obstruction syndrome (hepatic veno--occlusive disease), J Clin Exp Hepatol. déc, vol.4, issue.4, pp.332-378, 2014.

P. G. Richardson, M. L. Riches, N. A. Kernan, J. A. Brochstein, S. Mineishi et al., Phase 3 trial of defibrotide for the treatment of severe veno--occlusive disease and multi--organ failure, Blood. 31 mars, vol.127, issue.13, pp.1656-65, 2016.

F. Obut, V. Kasinath, and R. Abdi, Post--bone marrow transplant thrombotic microangiopathy, Bone Marrow Transplant. juill, vol.51, issue.7, pp.891-898, 2016.

F. Fakhouri, J. Zuber, -. Frémeaux, V. Bacchi, and C. Loirat, Haemolytic uraemic syndrome, Lancet Lond Engl. 12 août, vol.390, pp.681-96, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02155934

J. Khosla, A. C. Yeh, T. R. Spitzer, and B. R. Dey, Hematopoietic stem cell transplant--associated thrombotic microangiopathy: current paradigm and novel therapies, Bone Marrow Transplant, vol.53, issue.2, pp.129-166, 2018.

S. Jodele, B. L. Laskin, C. E. Dandoy, K. C. Myers, -. El et al., A new paradigm: Diagnosis and management of HSCT--associated thrombotic microangiopathy as multi--system endothelial injury, Blood Rev. mai, vol.29, issue.3, pp.191-204, 2015.

S. Changsirikulchai, D. Myerson, K. A. Guthrie, G. B. Mcdonald, C. E. Alpers et al., Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis, Clin J Am Soc Nephrol CJASN. févr, vol.4, issue.2, pp.345-53, 2009.

S. S. Kim, M. Patel, K. Yum, and A. Keyzner, Hematopoietic stem cell transplant--associated thrombotic microangiopathy: review of pharmacologic treatment options. Transfusion (Paris), févr, vol.55, issue.2, pp.452-460, 2015.

F. S. De-fontbrune, C. Galambrun, A. Sirvent, A. Huynh, S. Faguer et al., Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant--Associated Thrombotic Microangiopathy: A Study From the SFGM--TC, Transplantation. sept, vol.99, issue.9, pp.1953-1962, 2015.

K. Raj, A. Pagliuca, K. Bradstock, V. Noriega, V. Potter et al., Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced--intensity conditioning, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. juin, vol.20, issue.6, pp.890-895, 2014.

S. R. Mccurdy, J. A. Kanakry, M. M. Showel, H. Tsai, -. Bolaños et al., Risk--stratified outcomes of nonmyeloablative HLA--haploidentical BMT with high--dose posttransplantation cyclophosphamide, Blood. 7 mai, vol.125, issue.19, pp.3024-3055, 2015.

A. Desjonqueres, M. Illiaquer, A. Duquesne, L. Bris, Y. Peterlin et al., Longer delay of hematological recovery and increased transfusion needs after haploidentical compared to non--haploidentical stem cell transplantation, Bone Marrow Transplant. août, vol.51, issue.8, pp.1150-1152, 2016.

A. Bashey, M. Zhang, S. R. Mccurdy, . St, A. Martin et al., Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T--Cell-Replete Haploidentical Donor Transplantation Using Post--Transplant Cyclophosphamide, J Clin Oncol, vol.35, issue.26, pp.3002-3011, 2017.

M. Slade, J. F. Dipersio, P. Westervelt, R. Vij, M. A. Schroeder et al., Haploidentical Hematopoietic Cell Transplant with Post--Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.23, issue.10, pp.1736-1779, 2017.

R. L. Siegel, K. D. Miller, and A. Jemal, Cancer statistics, Cancer Statistics, vol.66, pp.7-30, 2016.

A. H. Filipovich, D. Weisdorf, S. Pavletic, G. Socie, J. R. Wingard et al., National Institutes of Health consensus development project on criteria for clinical trials in chronic graft--versus--host disease: I. Diagnosis and staging working group report, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. déc, vol.11, issue.12, pp.945-56, 2005.

M. Solh, C. Brunstein, S. Morgan, and D. Weisdorf, Platelet and Red Blood Cell Utilization and Transfusion Independence in Umbilical Cord Blood and Allogeneic Peripheral Blood Hematopoietic Cell Transplants, Biol Blood Marrow Transplant. mai, vol.17, issue.5, pp.710-716, 2011.

C. A. Rodrigues, V. Rocha, P. Dreger, C. Brunstein, H. Sengeloev et al., Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced--intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood, Haematologica. févr, vol.99, issue.2, pp.370-377, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01325615

N. Matsuno, A. Wake, N. Uchida, K. Ishiwata, H. Araoka et al., Impact of HLA disparity in the graft--versus--host direction on engraftment in adult patients receiving reduced--intensity cord blood transplantation, Blood. 20 août, vol.114, issue.8, pp.1689-95, 2009.

M. Remberger, J. Törlén, O. Ringdén, M. Engström, E. Watz et al., Effect of Total Nucleated and CD34(+) Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. mai, vol.21, issue.5, pp.889-93, 2015.

C. Yamamoto, H. Ogawa, T. Fukuda, A. Igarashi, H. Okumura et al., Impact of a Low CD34+ Cell Dose on Allogeneic Peripheral Blood Stem Cell Transplantation, Biol Blood Marrow Transplant. avr, vol.24, issue.4, pp.708-724, 2018.

K. A. Marr, R. A. Carter, M. Boeckh, P. Martin, and L. Corey, Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors, Blood. 15 déc, vol.100, issue.13, pp.4358-66, 2002.

C. Junghanss, K. A. Marr, R. A. Carter, B. M. Sandmaier, M. B. Maris et al., Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.8, issue.9, pp.512-532, 2002.

S. Ali, J. D. Pimentel, J. Munoz, V. Shah, R. Mckinnon et al., Iron overload in allogeneic hematopoietic stem cell transplant recipients, Arch Pathol Lab Med. mai, vol.136, issue.5, pp.532-540, 2012.

L. K. Vande-vusse, D. K. Madtes, K. A. Guthrie, T. B. Gernsheimer, J. R. Curtis et al., The association between red blood cell and platelet transfusion and subsequently developing idiopathic pneumonia syndrome after hematopoietic stem cell transplantation, Transfusion (Paris). avr, vol.54, issue.4, pp.1071-80, 2014.

A. R. Harvey, S. V. Basavaraju, K. Chung, and M. J. Kuehnert, Transfusion--related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, Transfusion (Paris). avr, vol.55, issue.4, pp.709-727, 2010.

T. Konuma, M. Oiwa--monna, M. Mizusawa, M. Isobe, S. Kato et al., Red blood cell transfusion burden by day 30 predicts mortality in adults after single--unit cord blood transplantation, Bone Marrow Transplant, vol.54, issue.11, pp.1836-1882, 2019.

S. Hosoba, E. K. Waller, N. Shenvi, M. Graiser, K. A. Easley et al., Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft--versus--Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.24, issue.5, pp.973-82, 2018.

A. Dominietto, A. M. Raiola, M. T. Van-lint, T. Lamparelli, F. Gualandi et al., Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft--versus--host disease, donor type, cytomegalovirus infections and cell dose, Br J Haematol. janv, vol.112, issue.1, pp.219-246, 2001.

P. Pihlstedt, T. Paulin, B. Sundberg, B. Nilsson, and O. Ringdén, Blood transfusion in marrow graft recipients, Ann Hematol. août, vol.65, issue.2, pp.66-70, 1992.

B. Bolwell, B. Pohlman, R. Sobecks, S. Andresen, S. Brown et al., Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant, Bone Marrow Transplant. févr, vol.33, issue.4, pp.419-442, 2004.

D. Dahl, A. Hahn, C. Koenecke, H. Heuft, E. Dammann et al., Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: identification of patients at risk. Transfusion (Paris), mars, vol.50, issue.3, pp.649-55, 2010.

J. P. Sommadossi and R. Carlisle, dihydroxy--2--propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro, Antimicrob Agents Chemother. mars, vol.9, issue.1, pp.452-456, 1987.

M. L. Green, W. Leisenring, H. Xie, T. C. Mast, Y. Cui et al., Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre--emptive therapy: a retrospective cohort study, Lancet Haematol. mars, vol.3, issue.3, pp.119-127, 2016.

F. Locatelli, A. Bertaina, V. Bertaina, and P. Merli, Cytomegalovirus in hematopoietic stem cell transplant recipients --management of infection, Expert Rev Hematol, vol.9, issue.11, pp.1093-105, 2016.

T. Prébet, P. Ladaique, M. Ferrando, C. Chabannon, C. Faucher et al., Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation, Exp Hematol. janv, vol.38, issue.1, pp.55-60, 2010.

Y. Kong, Y. Chang, Y. Wang, Y. Chen, W. Han et al., Association of an Impaired Bone Marrow Microenvironment with Secondary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation, Biol Blood Marrow Transplant. oct, vol.19, issue.10, pp.1465-73, 2013.

Y. Sun, G. He, Y. Chang, L. Xu, X. Zhang et al., The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation, Ann Hematol, vol.94, issue.10, pp.1699-705, 2015.

Y. Chang, X. Zhao, L. Xu, X. Zhang, Y. Wang et al., Donor--specific anti--human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets, J Hematol OncolJ Hematol Oncol, vol.8, issue.1, p.84, 2015.

Y. Kong, Y. Wang, Y. Hu, W. Han, Y. Chang et al., The bone marrow microenvironment is similarly impaired in allogeneic hematopoietic stem cell transplantation patients with early and late poor graft function, Bone Marrow Transplant. févr, vol.51, issue.2, pp.249-55, 2016.

R. P. Gale, Early and late graft--failure after transplants, Bone Marrow Transplant. févr, vol.51, issue.2, pp.182-185, 2016.

G. Battipaglia, A. Ruggeri, E. Brissot, A. Mamez, F. Malard et al., Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation, Bone Marrow Transplant. déc, vol.50, issue.12, pp.1574-1581, 2015.

T. Tanaka, Y. Inamoto, T. Yamashita, S. Fuji, K. Okinaka et al., Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation, Biol Blood Marrow Transplant. mai, vol.22, issue.5, pp.919-943, 2016.

X. Zhao, X. Zhao, M. Huo, Q. Fan, P. X. Wang et al., Donor--Specific Anti--Human Leukocyte Antigen Antibodies Predict Prolonged Isolated Thrombocytopenia and Inferior Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation, J Immunol Res, vol.2017, pp.1-8, 2017.

M. Mohty, C. Faucher, C. Chabannon, N. Vey, A. M. Stoppa et al., CD34(+) immunoselected cells for poor graft function following allogeneic BMT, Cytotherapy, vol.2, issue.5, pp.367-70, 2000.

A. Larocca, G. Piaggio, M. Podestà, A. Pitto, B. Bruno et al., Boost of CD34+--selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation, Haematologica. juill, vol.91, issue.7, pp.935-975, 2006.

B. Askaa, -. Fischer, A. -nielsen, L. Vindeløv, E. K. Haastrup et al., Treatment of poor graft function after allogeneic hematopoietic cell transplantation with a booster of CD34--selected cells infused without conditioning, Bone Marrow Transplant. mai, vol.49, issue.5, pp.720-721, 2014.

E. Klyuchnikov, J. El--cheikh, A. Sputtek, M. Lioznov, B. Calmels et al., CD34(+)--selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. mars, vol.20, issue.3, pp.382-388, 2014.

S. P. Haen, M. Schumm, C. Faul, L. Kanz, W. A. Bethge et al., Poor graft function can be durably and safely improved by CD34+--selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation, J Cancer Res Clin Oncol. déc, vol.141, issue.12, pp.2241-51, 2015.

A. Ghobadi, M. A. Fiala, G. Ramsingh, F. Gao, C. N. Abboud et al., Fresh or Cryopreserved CD34 + --Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation, Biol Blood Marrow Transplant. juill, vol.23, issue.7, pp.1072-1079, 2017.

!. and +. ,

, /01234564789+:+;(-+:+61<864=><+?7@1+!796A5BB7C1<DD<E+FGH+:+I78I<8612+J<+CB70@B<9+17@C<9E+48J2!+:+ 48J2!<8J58I<E+FK+:+I78I<8612+J<+!B5L@<66<9+JM5!N21=9<+7@+>2B58C<+J<+I78I<8612+J<+ !B5L@<66<9E+KOO+:+!7BP8@IB541<9+8<@617!N4B<9

$. !&quot;#-$%-&amp;-;-*+ and !. , /012034 56#5 -#6), vol.698, pp.56-62

, $30#$45!6 -<=>(?(FGH'4 56"* -#6)

$. , , vol.20, pp.69-78

. #6*e--#6, #, issue.7, pp.56-60

$. ,

!. ##-$%-&amp;-;-*+, $. , !. , and #. , 5#74 #5:98 %&' (

, ?@A<4 #59) -#57)(6(D5#74 #5E) #5:: -#5"#, vol.84, p.5

$. 30#$, , vol.45

$. ,

, 5#84 #5#89, #E, vol.5, issue.6, pp.8-13

. Hq,

, @C(0@31

. Viii-serment-d&apos;hippocrate,

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux. Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Je ferai tout pour soulager les souffrances. Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément. Je préserverai l'indépendance nécessaire à l'accomplissement de ma mission

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses

, que je sois déshonoré et méprisé si j'y manque